Table 1.
Characteristic | HIV-Uninfected Female Partners | HIV-Infected Male Partners |
---|---|---|
Age, y | 32.0 (27.0–37.7) | 37.6 (32.7–43.1) |
Education duration, y | 7.0 (4.0–9.0) | 7.0 (5.0–11.0) |
Effective contraceptive usea | 1044/2751 (37.9) | … |
Medical | ||
Circumcised | … | 909/2750 (33.1) |
Sexually transmitted infectionb | 852/2017 (30.1) | 220/2751 (8.0) |
HSV-2 seropositive | 2230/2709 (82.3) | 1167/2751 (42.4)c |
Sex acts in past 30 d, no. | ||
Any act with study partner | 4.0 (2.0–8.0) | 4.0 (2.0–8.0) |
Any act with study partner protected by a condom | 3.0 (1.0–6.0) | 3.0 (2.0–6.0) |
Any condomless act with study partner | 670/2751 (24.4) | 706/2751 (25.7) |
Any act with additional partner | 10/2751 (0.4) | 338/2751 (12.3) |
HIV-associated clinical data | ||
Plasma HIV RNA viral load, log10 copies/mL | … | 4.2 (3.5–4.8) |
CD4 T-cell count, cells/mm3 | … | 447.0 (347.0–584.0) |
Female and Male Partners Combinedd | ||
Partnership duration, y | 9.7 (4.4–16.6) | |
Married to study partner | 2536/2751 (92.2) | |
Living together | 2656/2751 (96.6) | |
Living children with study partner, no. | 2.0 (1.0–4.0) |
Data are no. (%) of partners or couples or median values (interquartile ranges).
Abbreviation: HSV-2, herpes simplex virus type 2.
aIncludes implanted devices, injectable agents, oral contraceptive pills, intrauterine devices, and permanent methods.
bLaboratory diagnosis of Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum, Trichomonas vaginalis, HSV2, or bacterial vaginosis (female partners only).
c1,319 men tested at enrollment. Missing data (men not tested) included in denominator.
dReported by the HIV-uninfected female.